Table 2.
Comparison of operative characteristics stratified by number of NETLMs treated
| Overall | 1–5 Treated NETLMs | 6–10 Treated NETLMs | >10 Treated NETLMs | P value | |
|---|---|---|---|---|---|
| Median lesions preop (range) | 10 (0–100) | 3 (0–60) | 9 (1–100) | 20 (1–100) | < .01 |
| Median % liver replacement (range) | 10 (0–70%) | 2 (0–55%) | 10 (2–60%) | 15 (2–70%) | < .01 |
| Primary resected | 139 ( 74%) | 54 (74%) | 41 (76%) | 44 (72%) | .87 |
| Median % tumor debulked (range) | 85 (0–100%) | 95 (0–100%) | 80 (20–100%) | 80 (50–100%) | .01 |
| Mean % tumor debulked (range) | 78.7 (0–100%) | 79.3 (0–100%) | 78.2 (20–100%) | 78.4 (50–100%) | .95 |
| Number reaching 70% cytoreduction | 138 (79%) | 50 (76%) | 41 (84%) | 47 (78%) | .62 |
| Biochemical response | 111 (69%) | 42 (71%) | 30 (67%) | 39 (68%) | .88 |
| Symptomatic response | 80 (45%) | 28 (42%) | 17 (33%) | 35 (60%) | .03 |
| All complications | 98 (52%) | 35 (48%) | 33 (61%) | 30 (49%) | .29 |
| Major complications (grade 3, 4) | 28 (15%) | 10 (14%) | 7 (13%) | 11 (18%) | .76 |
| Median overall survival (95% CI, months) | 89 (72.6 – NR) | 80 (65.9 – NR) | 131.5 (72.6 – NR) | 89 (67.3 – NR) | .55 |
| Median progression-free survival (95% CI, months) | 22.5 (18.8 – 31.8) | 23.3 (18.2 – 56.1) | 21.6 (18.1 – 38.4) | 21.8 (17 – 3.7) | .55 |